Breaking News
November 17, 2018 - Tracking Preemies’ Head Size May Yield IQ Clues
November 17, 2018 - Scientists call for unified standards in 3-D genome and epigenetic data
November 17, 2018 - Lab Innovations 2018 has beaten all records by attracting 3,113 attendees
November 17, 2018 - Sexuality education before age 18 may reduce risk of sexual assault in college
November 17, 2018 - Lab Innovations 2018 confirmed as a major hit with visitors, exhibitors and speakers
November 17, 2018 - Largest parasitic worm genetic study hatches novel treatment possibilities
November 17, 2018 - Obesity significantly increases risk of Type 2 diabetes and coronary artery disease
November 17, 2018 - People with rare cancers can benefit from genomic profiling, shows research
November 17, 2018 - NIH awards over $1.8 million to husband-and-wife doctors to test new breast cancer approach
November 17, 2018 - Four-in-one antibody used to fight flu shows promise in mice
November 17, 2018 - New approach allows pathogens to be starved by blocking important enzymes
November 17, 2018 - Higher body mass index could cause depression even without health problems
November 17, 2018 - Protein which plays role in sensing cell damage serves as new target to treat pulmonary hypertension
November 17, 2018 - FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
November 17, 2018 - ID specialist input improves outcomes for outpatient parenteral antimicrobial therapy
November 17, 2018 - UT Southwestern scientists selected to receive 2019 Edith and Peter O’Donnell Awards
November 17, 2018 - New clinical algorithm to help individuals manage type 2 diabetes when fasting during Ramadan
November 17, 2018 - Researchers identify LZTR1 as evolutionarily conserved component of RAS pathway
November 17, 2018 - Heart Disease Leading Cause of Death in Low-Income Counties
November 17, 2018 - Estrogen Levels Test: MedlinePlus Lab Test Information
November 17, 2018 - Research reveals link between immunity, diabetes
November 17, 2018 - Research shows how to achieve improved smoking cessation outcomes within California’s Medicaid population
November 17, 2018 - New study finds less understanding and implementation of patient engagement
November 17, 2018 - New shoe insole technology could help diabetic ulcers heal better while walking
November 17, 2018 - New method to extend cell division and immortalization of avian-derived cells
November 17, 2018 - Australian Academy of Science urges parents to vaccinate children against meningococcal disease
November 17, 2018 - Hot water treatment may help improve inflammation and metabolism in sedentary people
November 17, 2018 - Researchers produce 3D chemical maps of small biological samples
November 17, 2018 - Must Blood Pressure Rise Wth Age? Remote Tribes Hold Clues
November 17, 2018 - Noonan Syndrome
November 17, 2018 - Interventions to delay and prevent type 2 diabetes are underused, researchers say
November 17, 2018 - Hackathon prize winner seeks to remotely monitor patient skin conditions
November 17, 2018 - Research team identifies Ashkenazi Jewish founder mutation for Leigh syndrome
November 17, 2018 - Gene editing could be used to halt kidney disease in patients with Joubert syndrome
November 17, 2018 - Study uncovers link between gut disruption and aging
November 17, 2018 - Teens more likely to pick up smoking after exposure from friends and family
November 17, 2018 - Nicoya designate the Institute for Stem Cell Biology and Regenerative Medicine as the OpenSPR Centre of Excellence
November 17, 2018 - new horizon in dental, oral and craniofacial research
November 17, 2018 - How does poor air quality affect your health?
November 17, 2018 - New device can regulate children’s blood glucose more like natural pancreas
November 17, 2018 - Game-Changers in Western Blotting and Protein Analysis
November 17, 2018 - FDA announces new actions to limit sale of e-cigarettes to youth
November 17, 2018 - Warmer winter temperatures related to higher crime rates
November 17, 2018 - MCO places increasing emphasis on helping people find and access healthy food
November 17, 2018 - Group of students aim to improve malaria diagnosis using old smartphones
November 17, 2018 - Transplantation of feces may protect preterm children from deadly bowel disease
November 17, 2018 - Researchers explore whether low-gluten diets can be recommended for people without allergies
November 17, 2018 - New and better marker for assessing patients after cardiac arrest
November 17, 2018 - For 7-year-old with failing bone marrow, a life-saving transplant | News Center
November 17, 2018 - New first-line treatment for peripheral T-cell lymphoma approved by FDA
November 17, 2018 - Artificial intelligence could be valuable tool to help young victims disclose traumatic testimony
November 17, 2018 - Breakthrough in the treatment of Restless Legs Syndrome
November 16, 2018 - FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
November 16, 2018 - Eagle Books | Native Diabetes Wellness Program
November 16, 2018 - Patients with common heart failure more likely to have lethal heart rhythms
November 16, 2018 - How AI could help veterinarians code their notes | News Center
November 16, 2018 - Bias-based bullying does more harm to students than generalized bullying
November 16, 2018 - Researchers find first direct evidence that cerebellum plays role in cognitive functions
November 16, 2018 - Non-coding genetic variant plays key role in endothelial function and disease incidence
November 16, 2018 - EMA recommends first all-oral treatment to tackle deadly sleeping sickness
November 16, 2018 - Drug used to treat dizziness may slow down growth of triple-negative breast cancer
November 16, 2018 - AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides
November 16, 2018 - ‘Orphan’ RNAs make cancer deadlier, but potentially easier to diagnose
November 16, 2018 - Air Cube touches down at hospital | News Center
November 16, 2018 - CRISPR-based tool shown to enhance cell-based immunotherapy
November 16, 2018 - Mechanisms that govern HIV latency differ in the gut and blood, finds study
November 16, 2018 - Researchers unravel mystery of NPM1 protein in acute myeloid leukemia
November 16, 2018 - High school students less likely to select milk, fruit for lunch when fruit juice is available
November 16, 2018 - Football coaches with great emotional competence are more successful
November 16, 2018 - Researchers awarded $10 million grant to address root causes of asthma in Puerto Rico
November 16, 2018 - Personalized scheduling of radiotherapy using genetic data could reduce side effects
November 16, 2018 - American Cancer Society study links social isolation to higher mortality risk
November 16, 2018 - Health Tip: Manage Morning Sickness
November 16, 2018 - Long term exposure to road traffic noise linked with greater obesity risk
November 16, 2018 - Infant gut microbes altered by mother’s obesity may increase risk for future disease
November 16, 2018 - Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
November 16, 2018 - ACC Latin America Conference brings experts to discuss latest cardiovascular science
November 16, 2018 - Pooled analysis of Intersect ENT’s steroid releasing implants in patients after frontal sinus surgery to be published
November 16, 2018 - Expectations about pain intensity can become self-fulfilling prophecies
November 16, 2018 - NIH awards $3.4 million to UC researchers to study gastrointestinal lymphatic system
Innovative drugs and new European treatment guidelines refine, improve MS therapy

Innovative drugs and new European treatment guidelines refine, improve MS therapy

image_pdfDownload PDFimage_print

MS is the most common neurological disease in young adults. There are about 2.3 million people worldwide who face a high risk of ever worsening disabilities from this disease. This year, two innovative drugs were approved in the EU, namely, cladribine, an active agent originally used in cancer therapy, and the monoclonal antibody ocrelizumab. This marks the approval of the first drug for combating primary chronic progressive MS, a form of the disease characterized by continuously worsening symptoms from the onset. In parallel to that and at the initiative of EAN and ECTRIMS, neurologists from 13 countries drew up recommendations for MS treatment in Europe. The new treatment guideline supports physicians in weighing the opportunities and risks of the available treatment options when making therapy decisions.

There are about 2.3 million people worldwide who are suffering from multiple sclerosis (MS), the most common neurological disease in young adults. Three to four times as many women as men are affected by this chronic inflammatory disease of the central nervous system and its risk of progressive disability. “Promising new drugs and the treatment guideline published this year by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) will further refine and improve the treatment of MS in substantial ways,” EAN President Prof Günther Deuschl (Kiel, Germany) said at the occasion of the 4th Congress of the EAN in Lisbon, where broad-based discussions of the new advances in MS therapy are conducted.

For 85 to 90 percent of the patients, MS begins as a relapsing-remitting disease. But there are also patients for whom the disease takes a primary progressive course. For them, the complaints worsen continuously from the onset. Without competent treatment, a large share of the patients with relapsing-remitting MS would enter a secondary progressive phase where existing symptoms constantly worsen.

Treatment goal: maximize prevention of relapses and disability progression

Until the mid-1990s, drug therapy was only possible for acute MS relapses. With the first disease-modifying therapies such as interferons beta or glatiramer acetate, it became possible to reduce the annual relapse rate by about one third. Since then, many new drugs including monoclonal antibodies have become available which target specific immune mechanisms to be even more effective and convenient. “MS treatment today is focused on avoiding relapses to the greatest possible extent and to halt the progression of disability. However, some of these drugs may also cause dangerous side effects which have to be considered when counseling our patients,” says Prof Franz Fazekas, EAN President elect who was also involved in the development of the European MS guidelines. With competent treatment, disease control has been achieved for 80 to 85 percent of the patients by suppressing the chronic inflammatory disease of the central nervous system as effectively as possible.

Cladribine and ocrelizumab: new options expanding MS treatment

Two new drugs and forms of treatment were recently approved in the EU and should help to bring about further optimization. Cladribine was originally used in anti-cancer treatment. Its mode of action on the immune system allows administering it in a pulse like manner with long lasting effects on the lymphocytes and beyond. Patients undergoing this treatment take cladribine tablets for 14 days, followed by a one-year break in treatment. In the second year, a 14-day treatment is prescribed as therapy, finally giving way to a two-year post-observation period. While this is a convenient and exciting concept it is not yet clear in how many patients and for how long such treatment will eventually succeed to silence MS activity and what to exactly do if new relapses occur. Long-term experience will be necessary to fully appreciate the safety profile of this drug.

The second new MS therapy is the monoclonal antibody ocrelizumab, approved since the beginning of the year in the EU for treatment of active relapsing-remitting MS, but also for patients with early primary chronic progressive MS. Prof Fazekas: “There had not been any therapy for these patients before.” Ocrelizumab has a targeted effect on the B cells of the immune system, which play a part in MS.

Following an initial application, further treatment with ocrelizumab entails infusions every six months. Long-term safety data are badly awaited also in this case. Prof Fazekas: “The possibility to choose among many drugs allows neurologists to adapt MS treatment to the individual needs of their patients and along the course of their disease. MS diagnosis means that patients have to live with the condition for 60 or 70 years, so we have to help them to control MS as efficiently as possible considering both benefits and risks.”

New treatment guideline assists physicians with their choice of therapy

At the initiative of the EAN and ECTRIMS, neurologists from 13 countries drew up 21 recommendations for MS treatment. The new European treatment guideline is based on the analysis of clinical studies and supports physicians in weighing the opportunities and risks of the available treatment options when making therapy decisions. Prof Deuschl: “This new guideline is part of the EAN guideline program under which all important neurological diseases are to be reappraised. About 20 of the guidelines are currently being worked on,” Prof Deuschl added. “These efforts underscore the major significance of the EAN, which is working through overarching topics of this kind and thus providing important principles not only to medical practitioners but also for health care policy.”

Tagged with:

About author

Related Articles